Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00743002 · ClinicalTrials.gov registry record · Phase 2
A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione
A Phase 2 study, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT00743002 is a Phase 2 study that has completed, run by OPKO Health. The registered enrollment target is 87 participants.
The verdict
NCT00743002, a Phase 2 study, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
This trial is designed to show the effect of treatment with TT223 or placebo on blood glucose control after 12 weeks of treatment with a 6 month follow-up. TT223 is administered by injection once daily to patients currently treated with Metformin and/or Thiazolidinedione.
Interventions
- DRUG TT223 with Metformin and/or TZD
- DRUG Placebo with Metformin and/or TZD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00743002
The ClinicalTrials.gov registry entry for NCT00743002 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TT223 with Metformin and/or TZD is the first listed.
NCT00743002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00743002 about?
NCT00743002 is a clinical study titled "A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione". This trial is designed to show the effect of treatment with TT223 or placebo on blood glucose control after 12 weeks of treatment with a 6 month follow-up. TT223 is administered by injection once daily to patients currently treated with Metformin and/or Thiazolidinedione.
What is the current status of trial NCT00743002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2008-08. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00743002?
The interventions under investigation include: TT223 with Metformin and/or TZD (DRUG), Placebo with Metformin and/or TZD (DRUG).
Who is sponsoring clinical trial NCT00743002?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.